TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity of identification of referable and non-referable Diabetic Retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Specificity of identification of referable and non-referable Diabetic Retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: FeNO change from baseline to week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of EBV-positive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of EBV within the endothelial cell line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's overall satisfaction with his teeth at the end of orthodontic treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: uptake of postnatal visits
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: postpartum family planning adoption
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: exclusive breast feeding practice
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with reoccurring VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Antibiotic Free Days
Endpoint domain: Resource use
Primary endpoint: Change in measured serum cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cell number of individual lymphocyte subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with clinically relevant changes from baseline electrocardiogram (ECG) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in flexibility of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: late lumen loss at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of atorvastatin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of atorvastatin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum standardized uptake value in the tumour lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: suicidal ideation severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gingival inflammation measured by Gingival Index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival inflammation measured by Gingival Bleeding Index (GBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the GSV and SSV diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Heavy legs severity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of labial bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White Cell Count (WCC) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants voting consistently
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inflammatory cytokine biomarker (IL-6 and TNF-alpha) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory cytokine biomarker (C-reactive protein) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative abundance of metabolites in plasma samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composition of gut microbiota bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular vital parameter - heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular vital parameter - blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum biomarker - DHEA/Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the BCI command delivery performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the focality and Strength of SMR Modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total opioids use for 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: peripheral endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid Consumption in Oral Morphine Milliequivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of umbilical cord mesenchymal stem cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of underdosing event of antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of doses with regard to reported hallucinogenic or unpleasant effects
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ratings of Treatment Satisfaction (Likert Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Suicide Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically significant hematological and biochemical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Eating Disorder examination (EDE-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glucose variability and insulin resistance (CGMS - 10 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Index skin recoloration time (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver ultrasound parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postoperative Level of Frailty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the concentration versus time curve (AUC) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of withanolides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring treatment by surgeon for post-operative adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative aesthetic correction rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA response (PSA50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Oral Intake Scale-German (FOIS-G)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Scale (YS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified thrombolysis in cerebral infarction (mTICI) score of 2c-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Prevalence of pathogenic and likely pathogenic germline variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gingivitis measured by Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque measured by Lobene-Soparkar Modification of Turesky Modification of Quigley-Hein Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Stress - Biomarker Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Stress - Psychometric Measure Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Self-compassion - Biomarker Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Self-compassion - Psychometric Measure Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Virtual spatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change the prevalence of CRE colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change the prevalence of CRE transmission in the household
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Assessment the effectiveness of the hospital wastewater treatment on reducing CRE from hospital to community
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: acute Minimal Stent Area (MSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Low, Medium, and High Amyloid Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RAVLT Rey Auditory Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: visual acuity expressed as log MAR units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the proportion of patients with stable Scale for the assessment and rating of ataxia (SARA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiotocography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of nutritional risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevalence of dietary reduction and weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-acute COVID-19 lung sequelae traits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual analogue scale for dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale for vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AEs), serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cutaneous Symptom Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SkinDex-16 Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tobacco withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quantification of periodontal bacterial and viral species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion of vibriocidal titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of AKI transition to the more severe stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Stoma closure timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Platelet index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional outcome after supracondylar humeral fracture
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of individuals with neutralising antibodies against WNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of individuals with neutralising antibodies against USUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gross Motor Functional Classification Scale - Expanded and revised (GMFCS-E&R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jenkins Sleep Evaluation Questionnaire (JSEQ) - Danish version
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Response to neoadjuvant immunochemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Cortisol Slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax,ss of BR1015-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of BR1015-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of BR1015-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of BR1015-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of Regrowth Maintenance (LOM) Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of Regrowth (ROR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Eular Sjögren's Disease Activity Index (ESSDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Physician's Global Assessment Scale (PhGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORE2-OP risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost per Year of Use of Resources for Medical Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Costs per Year of Use of Resources for Medical Tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per Year of Use of Resources for Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distance of canine retraction in millimeters per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common bile duct stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in percent prostate infiltrating CD8+ T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Ease of Lens Handling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Coefficient of variation (in %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Amplitude Triggering Patient Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Frequency Triggering Patient Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Width Triggering Patient Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Leak Point Pressure (LPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of All Study-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Increase in Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to all visible lesion(s) resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Acute Metabolic Rejection (AMR)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of response (DoR) among responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sexual functioning after MI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary Endpoint 1
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Number of participants with dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in IKDC scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Questionnaire validity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Questionnaire reproducibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement between self reported and non-self reported version of ALSFRS-R
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants with pain freedom at 2 hours post dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with an MBS reported before dosing that is absent at 2 hours post dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emgraftment Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Graft-Versus-Host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Graft-Versus-Host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Appendicular lean muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hemi-diaphragmatic paresis
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to recruit to target participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in Tricuspid Regurgitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants Implanted without Major Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of photoreceptor and retinal pigment epithelium (RPE) cell layers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPE cell morphology changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cone Photoreceptor Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean 16-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with optimal vaginal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of financial catastrophe
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Levels of financial distress
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 40 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Weekly Urticaria Score (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weekly Itch Severity Score (ISS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weekly Hives Severity Score (HSS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Improvement by at Least Two Categories on a Six Category Ordinal Scale at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from clinically significant AF or atrial arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VX1/Volta AF-Xplorer/Volta AF-Xplorer II-related Incident rate during ablation procedure
Endpoint domain: Adverse events/effects
Primary endpoint: VX1/Volta AF-Xplorer/Volta AF-Xplorer II-related Adverse Event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentration of Vatiquinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Vatiquinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-from-baseline in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence or Absence of a replicative virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in total corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of LH secretory peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of concentration of progesterone >1 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lymphedema volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiography (LVEF, LVEDD and LVESD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Isometric Strength of Gastrocnemius Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes